Improving the Quality of Product Release - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving the Quality of Product Release
The authors discuss the role of quality-control automation in providing better data, enhanced compliance, and potentially faster release times.


Pharmaceutical Technology
Volume 35, Issue 1

Device integration

Integration of monitoring devices such as total organic carbon and endotoxin analyzers eliminates separate data flows from these respective devices and the problem of an analyst having to manually enter the data into another system such as a laboratory information management system (LIMS) database or spreadsheet. Data from these devices transfers directly into the system of record, eliminating paper data recording, manual reconciliation, and transfer and reformatting. The data from the devices is stored in a structured format to report, trend, and correlate the information obtained from other sources for immediate decision support.

System integration

Integrating the QC repository with in-process and continuous monitoring systems is a next crucial step in further automation. In-process data in a common format with manual QC data provides a single view across production and quality assurance. Anomalies in the sample can be correlated to the continuous monitoring performed when the manual sample was obtained. The single dataset can provide critical information to identify potential contamination events before they interrupt production. The primary objective is preventive action performed with real-time trend analysis, shorter investigation time, root-cause analysis, and immediate alerts for critical events. With these tools, system trends such as seasonal mold can be identified, and cleaning regimens adjusted proactively.

Comprehensive data reporting, analytics and trending tools, and a dedicated repository, or "data mart" combine relevant information sources from production and QC. Custom analytical views or "dashboards" combine key performance metrics and user alerts with targeted information that the user can apply in QC, production, or other production-release decisions. Trend analysis improves over time and across processes. More importantly, the information can be used as a common communication tool between QC and production. A QC test revealing contaminated water, for example, can be quickly communicated to production so that the water is not used in any process.

Product-release decisions

The value of an automated QC process is measured by its ability to support product-release decisions for a wide range of pharmaceutical products, thereby moving organizations toward the ultimate goal of release in full compliance with real-time information. QC information needs to meet the following four requirements to support product-release decisions:

  • A prioritized automated system must remove the bottlenecks and errors of manual data aggregation and redundant data entry. The system must also reduce sample life-cycle times.
  • The information must be detailed to support meaningful analysis. The information needed must provide maximum accuracy in a minimal amount of time to answer all investigation inquiries.
  • The information must be comprehensive. Information-management tools need to combine in-process monitoring, laboratory monitoring, and product testing into a complete, role-based picture for decision makers.
  • The information must be actionable. Dynamic maps and trends must be produced in seconds. There must be immediate alerts for out-of-specification events to initiate investigation processes. Visual tools and on-demand trends are needed for preventive action along with clear and detailed standardized reports for release records and regulatory audits.

Conclusion

The benefits of automatic mobile data acquisition and workflow, device and in-process integration, and common analytical standards and tools include increased productivity, improved compliance, and faster product-release decisions. A fully integrated QC process using these technology solutions is an important part of any regulated organization's process analytical technology initiatives. An organization focused on producing high-quality, actionable QC information has the ability to continuously improve a production process focused on delivering product of the highest quality with maximum efficiency.

Michael Goetter is director of informatics strategy, Lonza Wayne Inc., 1255 Drummers Lane, Suite 202, Wayne, PA 19087, tel. 484.253.1000 ext 101, fax 484.253.4054,
Jeremy Tanner is product specialist, Lonza Walkersville Inc.

*To whom all correspondence should be addressed.

Reference

1. FDA, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice (Rockville, MD 2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
67%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
33%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here